Billions for biotech

Maryland Governor Martin O'Malley announced his proposal to invest $1.1 billion in biotech industry, which could trump the $1 billion already signed by Massachusetts Governor Deval Patrick on Monday (June 16). Now the race for the biggest biotech hub on the east coast begins in earnest. Maryland's proposal, which O'Malley discussed during a visit to Johns Hopkins University yesterday, would allot funds for a biotechnology center, start-up companies, and $20 million annually for stem cell resea

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Maryland Governor Martin O'Malley announced his proposal to invest $1.1 billion in biotech industry, which could trump the $1 billion already signed by Massachusetts Governor Deval Patrick on Monday (June 16). Now the race for the biggest biotech hub on the east coast begins in earnest. Maryland's proposal, which O'Malley discussed during a visit to Johns Hopkins University yesterday, would allot funds for a biotechnology center, start-up companies, and $20 million annually for stem cell research. "We certainly see manufacturing has been on the decline in the past, and life sciences are really the new manufacturing for the 21st century." Donald C. Fry, president of the Greater Baltimore Committee told linkurl:__The Baltimore Sun.__;http://www.baltimoresun.com/news/health/bal-bioscience0616,0,6308709.story The bill may face some resistance in the state legislature, which downgraded a $23 million allotment for stem cells to $19 million this year. One of the provisions of the Massachusetts biotech bill will support young scientists with grants ranging from $5,000 to $15,000, to offset the low income of academic scientists in training. The program was named the Dr. Judah Folkman Higher Education Grant Fund, in honor of the cancer researcher and physician who linkurl:inspired many;http://www.the-scientist.com/blog/display/54173/ in the life sciences. "One of Judah's greatest gifts and passions was identifying brilliant young scientists and supporting and investing in them during the early part of their careers," said James Mandell, president and CEO of Children's Hospital Boston, linkurl:in a statement.;http://www.boston.com/news/health/blog/2008/06/life_sciences_b.html
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo